Abstracts tagged "DMARDs and rheumatoid arthritis (RA)"

Abstract Number: 484 • 2013 ACR/ARHP Annual Meeting
Response To Biologic Disease-Modifying Anti-Rheumatic Drugs After Discontinuation Of Anti-Tumor Necrosis Factor Alpha Agents In Rheumatoid Arthritis Patients
Eric Elkin¹, Max I. Hamburger², Tripthi Kamath³, Sarika Ogale³, Adam Turpcu³, Jae Oh⁴, Kristin King⁴, Monarch Shah¹ and Martin J. Bergman⁵, ¹ICON Clinical Research, San Francisco, CA, ²Rheumatology Associates, Melville, NY, ³Genentech, South San Francisco, CA, ⁴ICON Late Phase and Outcomes Research, San Francisco, CA, ⁵Taylor Hospital, Ridley Park, PA
Background/Purpose: Rheumatoid arthritis (RA) patients who have failed an anti-TNF agent as their first biologic agent have the option of switching to a second aTNF…
Abstract Number: 203 • 2013 ACR/ARHP Annual Meeting
Belief In Self-Adjustability Of Medication Dosing Is Negatively Correlated With Medication Adherence In Patients With Rheumatoid Arthritis
Wenxin Sun¹, Dianne Carrol Tan Bautista², Xiaohui Xin³, Yu Ting Saw³, Wee Boon Tan³, Kanchanadevi Balasubramaniam³, Wan Pin Lee⁴, Steve Thein Htay Oo³, Yin Bun Cheung² and Julian Thumboo⁵, ¹Duke-NUS Graduate Medical School, Singapore, Singapore, ²Center for Quantitative Medicine, Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore, Singapore, ³Academic Clinical Programme, Division of Medicine, Singapore General Hospital, Singapore, Singapore, ⁴Operation and Performance Management, Singapore General Hospital, Singapore, Singapore, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Medication adherence in Rheumatoid Arthritis (RA) is reported to be generally low. This major problem needs to be addressed because it leads to reduced…
Abstract Number: 193 • 2013 ACR/ARHP Annual Meeting
Physician Variability In Rheumatoid Patients Not Receiving Biologics Or Non-Biologic Dmards: Implications For Quality Reporting
Dimitrios A. Pappas¹, Lang Chen², Leslie R. Harrold³, George W. Reed⁴, Joel M. Kremer⁵, Jeffrey D. Greenberg⁶ and Jeffrey R. Curtis⁷, ¹Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Massachusetts Medical School, Worcester, MA, ⁴Corrona, LLC., Southborough, MA, ⁵Center for Rheumatology, Albany Medical College, Albany, NY, ⁶Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁷University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Current quality of care guidelines recommend that all patients with Rheumatoid Arthritis (RA) be treated with biologic and/or non-biologic (nb) DMARDs. However, some RA…
Abstract Number: 1468 • 2013 ACR/ARHP Annual Meeting
Reasons For Discontinuation Of Biologic Agents In Rheumatoid Arthritis Patients
Eric Elkin¹, Martin J. Bergman², Tripthi Kamath³, Sarika Ogale³, Adam Turpcu³, Kristin King⁴, Jae Oh⁴, Monarch Shah¹ and Max I. Hamburger⁵, ¹ICON Clinical Research, San Francisco, CA, ²Taylor Hospital, Ridley Park, PA, ³Genentech, South San Francisco, CA, ⁴ICON Late Phase and Outcomes Research, San Francisco, CA, ⁵Rheumatology Associates, Melville, NY
Background/Purpose: Results from randomized controlled trials indicate that about one-third of rheumatoid arthritis (RA) patients initially treated with anti-TNF agents do not respond, show a…
Abstract Number: 1422 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of a Novel Disease-Modifying Antirheumatic Drug, Iguratimod, As Add-On Therapy For Patients With Rheumatoid Arthritis
Daisuke Kobayashi¹, Satoshi Ito², Akira Murasawa¹, Ichiei Narita³ and Kiyoshi Nakazono¹, ¹Niigata Rheumatic Center, Shibata, Japan, ²Niigata Rheumatic Center, Niigata, Japan, ³Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: Iguratimod is a newly-developed disease-modifying antirheumatic drug (DMARD) that was approved in Japan in September 2012. It has been reported to suppress tumor necrosis…
Abstract Number: 2636 • 2012 ACR/ARHP Annual Meeting
Understanding Why Treat-to-Target Strategies Are Difficult to Follow
Liana Fraenkel¹, Meaghan Cunningham² and Paul Falzer³, ¹Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, ²Medicine, Yale University School of Medicine, New Haven, CT, ³Medicine, VA Connecticut Healthcare System, New Haven, CT
Background/Purpose: Treat-to-target (T2T) refers to a set of decision strategies widely advocated for the optimal management of rheumatoid arthritis (RA). Despite considerable evidence that this…
Abstract Number: 387 • 2012 ACR/ARHP Annual Meeting
Medication Choices and Medication Survival in a National Multicentre Community Based Rheumatoid Arthritis Cohort
Lynden Roberts¹, Kathleen Tymms², Julien P. de Jager³, Geoffrey O. Littlejohn⁴, Hedley Griffiths⁵, Dave Nicholls⁶, Paul Bird⁷, Julie Hill⁸, Philip McCloud⁸, James C. Scott⁹, Jane Zochling¹⁰ and OPAL Consortium¹¹, ¹School of Medicine, James Cook University, Townsville, Australia, ²Canberra Rheumatology, Canberra, ACT, Australia, ³Suite 2, Osler House, Southport, Australia, ⁴Rheumatology, Monash Medical Center, Melbourne, Australia, ⁵Barwon Rheumatology Service, Geelong, Australia, ⁶Coast Joint Care, Maroochydore, Australia, ⁷Combined Rheumatology Practice, Sydney, Australia, ⁸Statistics, McCloud Consulting Group, Sydney, Australia, ⁹Medical Affairs, Roche Products Pty Limited, Sydney, Australia, ¹⁰Menzies Research Institute Tasmania, Hobart, Australia, ¹¹Melbourne, Australia
Background/Purpose: A sizeable body of high-quality research underpins our knowledge of the efficacy of various RA therapies. Outside the controlled environment of these clinical trials,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].